NEW
Stock Screener with Intrinsic Value
Royalty Pharma plc (RPRX)
Last Price$30.8(0.6%)
Market Cap$13.8B
Intrinsic value score
7/10
Good
Intrinsic value
$204.5
DCF value - $356.7
Relative value - $52.3
Undervalued
565.0%
LTM P/E
12.0x
Peer set median (28.9x)
Discount rate
5.4%
RPRX Intrinsic value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
RPRX Historical Intrinsic Value
Crunching data... Almost there!
RPRX vs Peer Set: Intrinsic Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for RPRX
DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Royalty Pharma plc intrinsic value?
As of Jan 17, 2025, Royalty Pharma plc Intrinsic Value is $204.5. This suggests it may be undervalued by 565.0% compared to its current price of around $30.8.
What is Royalty Pharma plc DCF (discounted cash flow) valuation?
As of Jan 17, 2025, Royalty Pharma plc's Discounted Cash Flow (DCF) valuation estimates its share price at $356.6. This suggests it may be overvalued by 1,059.6% to its current price of around $30.8, using a discount rate of 5.4% and terminal growth rate of 3.0%.
Is Royalty Pharma plc overvalued or undervalued?
Royalty Pharma plc is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $204.5, compared to a market price of around $30.8. This suggests a potential undervaluation of 565.0%.